Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sunitinib Treatment Of Renal Adjuvant Cancer (s-TRAC): A Randomized Double-Blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RCC

Trial Profile

Sunitinib Treatment Of Renal Adjuvant Cancer (s-TRAC): A Randomized Double-Blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RCC

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms S-TRAC; S-TRAC
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Nov 2018 Results published in the Clinical Cancer Research
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results (n=605) of post hoc exploratory analysis assessing neutrophil-to-lymphocyte ratio as a potential prognostic factor for of disease-free survival in the renal cell carcinoma adjuvant setting, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top